FDA recall D-0482-2024

Breckenridge Pharmaceutical, Inc · Class II · drug

Product

Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, (a) 90-count bottles (NDC 51991-747-90), (b) 1000-count bottles (NDC 51991-747-10), Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.

Reason for recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Distribution

US Nationwide.

Key facts

Status
Ongoing
Initiation date
2024-04-29
Report date
2024-05-15
Voluntary/Mandated
Voluntary: Firm initiated
Location
Berlin, CT, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0482-2024